Policy changes Backwork has recorded, newest first. The most recent change on record is from October 14, 2026. Changes appear here after Backwork reviews and applies a refresh, so this page can trail the payers’ own sites.
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
83,427 on record
| Recorded | Payer | Policy | Change |
|---|---|---|---|
| Aug 2, 2026 | Point32Health | Office-Administered Medical Drugs Available through Specialty Pharmacies | New policy |
| Aug 2, 2026 | Point32Health | Office-Administered Medical Drugs Available through Specialty Pharmacies | New policy |
| Aug 2, 2026 | Point32Health | Office-Administered Medical Drugs Available through Specialty Pharmacies | New policy |
| Aug 2, 2026 | Point32Health | Nulibry (fosdenopterin) | New policy |
| Aug 2, 2026 | Point32Health | Nulibry (fosdenopterin) | New policy |
| Aug 2, 2026 | Point32Health | Niktimvo (axatilimab-csfr) | New policy |
| Aug 2, 2026 | Point32Health | Niktimvo (axatilimab-csfr) | New policy |
| Aug 2, 2026 | Point32Health | New-to-Market Drugs | New policy |
| Aug 2, 2026 | Point32Health | New-to-Market Drugs | New policy |
| Aug 2, 2026 | Point32Health | Multiple Sclerosis Agents | New policy |
| Aug 2, 2026 | Point32Health | Medicare Part B Step Therapy | New policy |
| Aug 2, 2026 | Point32Health | Medical Benefit Step Therapy | New policy |
| Aug 2, 2026 | Point32Health | Medical Benefit Step Therapy | New policy |
| Aug 2, 2026 | Point32Health | Medical Benefit Step Therapy | New policy |
| Aug 2, 2026 | Point32Health | MassHealth Adjudicated Payment Amount per Discharge and Adjudicated Payment per Episode Carve Out Drugs | New policy |
| Aug 2, 2026 | Point32Health | Lynozyfic (linvoseltamab-gcpt) | New policy |
| Aug 2, 2026 | Point32Health | Lynozyfic (linvoseltamab-gcpt) | New policy |
| Aug 2, 2026 | Point32Health | Lyfgenia (lovotibeglogene autotemcel) | New policy |
| Aug 2, 2026 | Point32Health | Lyfgenia (lovotibeglogene autotemcel) | New policy |
| Aug 2, 2026 | Point32Health | Luxturna (voretigene neparvovec-rzyl) | New policy |
| Aug 2, 2026 | Point32Health | Lunsumio (mosunetuzumab-axgb) | New policy |
| Aug 2, 2026 | Point32Health | Lunsumio (mosunetuzumab-axgb) | New policy |
| Aug 2, 2026 | Point32Health | Long-Acting Colony Stimulating Factor Products | New policy |
| Aug 2, 2026 | Point32Health | Leqvio (inclisiran) | New policy |
| Aug 2, 2026 | Point32Health | Leqvio (inclisiran) | New policy |
| Aug 2, 2026 | Point32Health | Leqembi (lecanemab) | New policy |
| Aug 2, 2026 | Point32Health | Leqembi (lecanemab) | New policy |
| Aug 2, 2026 | Point32Health | Lamzede (velmanase alfa-tycv) | New policy |
| Aug 2, 2026 | Point32Health | Lamzede (velmanase alfa-tycv) | New policy |
| Aug 2, 2026 | Point32Health | LENMELDY (atidarsagene autotemcel) | New policy |
| Aug 2, 2026 | Point32Health | Kymriah (tisagenlecleucel) | New policy |
| Aug 2, 2026 | Point32Health | Kymriah (tisagenlecleucel) | New policy |
| Aug 2, 2026 | Point32Health | Krystexxa (pegloticase) | New policy |
| Aug 2, 2026 | Point32Health | Kisunla (donanemab-azbt) | New policy |
| Aug 2, 2026 | Point32Health | Kisunla (donanemab) | New policy |
| Aug 2, 2026 | Point32Health | Kebilidi (eladocagene exuparvovectneq) | New policy |
| Aug 2, 2026 | Point32Health | Kebilidi (eladocagene exuparvovectneq) | New policy |
| Aug 2, 2026 | Point32Health | Kanuma (sebelipase alfa) | New policy |
| Aug 2, 2026 | Point32Health | Izervay (avacincaptad pegol) | New policy |
| Aug 2, 2026 | Point32Health | Izervay (avacincaptad pegol) | New policy |
| Aug 2, 2026 | Point32Health | Itvisma (onasemnogene abeparvovecbrve) | New policy |
| Aug 2, 2026 | Point32Health | Intravitreal Implants and Corticosteroid Inserts for Ophthalmic Conditions | New policy |
| Aug 2, 2026 | Point32Health | Intravenous Immune Globulin (IVIG) and Subcutaneous Immune Globulin (SCIG) Products | New policy |
| Aug 2, 2026 | Point32Health | Imaavy (nipocalimab) | New policy |
| Aug 2, 2026 | Point32Health | Imaavy (nipocalimab) | New policy |
| Aug 2, 2026 | Point32Health | Imaavy (nipocalimab) | New policy |
| Aug 2, 2026 | Point32Health | Ilaris (canakinumab) | New policy |
| Aug 2, 2026 | Point32Health | Ilaris (canakinumab) | New policy |
| Aug 2, 2026 | Point32Health | Hympavzi (marstacimab-hncq) | New policy |
| Aug 2, 2026 | Point32Health | Hympavzi (marstacimab-hncq) | New policy |